Q-omics provides the consensus-scored PCDHB3 profile across patient tissues and cancer cell-line models. PCDHB3 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHB3 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, PCDHB3 RNA expression shows 15,078 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KICH, and TGCT as cancer lineages where PCDHB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB3 survival associations across molecular data types. PCDHB3 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB3 RNA expression–survival associations across cancer types. High PCDHB3 expression shows unfavorable associations in BLCA, CESC, MESO, UCEC, BRCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHB3 RNA expression.
This table summarizes PCDHB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCDHB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB3 shows lower tumor expression in KICH, COAD, THCA, BRCA and BLCA and higher tumor expression in LIHC. The KICH box plot shows higher PCDHB3 RNA expression in normal versus tumor tissue (log2 FC = −1.490, t-test p < 0.001).
This table shows molecular features associated with PCDHB3 in patient tissues and cancer cell lines. In patient samples, PCDHB3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SOFT_TISSUE.
